Evidence map›Paper›PMID 40608091›Full record

ArticleAnnals of hematology2025

Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking?

Patrycja Zielińska, Karolina Gruenpeter, Agata Wieczorkiewicz-Kabut, Krzysztof Białas, Anna Koclęga, Izabela Noster, Izabela Szewczyk, Kinga Boral, Katarzyna Wiśniewska-Piąty, Aleksandra Butrym and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Patrycja ZielińskaDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland. pzielinska@sum.edu.pl.ORCID http://orcid.org/0000-0001-5215-5264
Karolina GruenpeterDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Agata Wieczorkiewicz-KabutDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Krzysztof BiałasDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Anna KoclęgaDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Izabela NosterDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Izabela SzewczykDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Kinga BoralDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Katarzyna Wiśniewska-PiątyDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.
Aleksandra ButrymDepartment of Cancer Prevention and Therapy, Wrocław Medical University, Wałbrzych, Poland.
Jarosław CzyżDepartment of Hematology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland.
Ewa LutwinDepartment of Hematology and Transplantology, Center of Oncology, Kielce, Poland.
Grzegorz HelbigDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, Katowice, 40-032, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second allogeneic stem cell transplantation (SCT2) presents a potentially curative treatment approach in patients who relapsed after first allogeneic transplant procedure. Currently there is no consensus on second allografting. The aim of our study was to analyze the outcome and prognostic factors of SCT2 in relapsed acute leukemia setting. The study comprised 60 patients at a median age of 44.7 years (37 females, 23 males) who underwent SCT2 due to relapsed acute leukemia between 2000 and 2024 in our center. Median remission duration after SCT1 was 13.6 (IQR 30.1) months and median time from relapse to SCT2 was 4 (IQR 3) months. Disease-risk index at SCT2 was as follows: low - 2 (3.3%), intermediate - 29 (48,4%), high - 27 (45%) and very high - 2 (3.3%). The same donor was used in 52 procedures (86.7%). Six patients died before engraftment due to severe infectious complications. The 2-year probability of overall survival (OS) and leukemia free survival (LFS) were 26.6% and 26.2%, respectively. Median follow-up after SCT2 was 10.7 (IQR 35) months. At the last follow-up, 22 patients (37%) were alive. The 2-year cumulative relapse incidence (RI) was 47.4% and cumulative non-relapse mortality (NRM) was 55.3%. The factors that adversely influenced survival were as follows: early relapse after SCT1 (< 6 months after transplantation) (p = 0.018) and the use of reduced intensity conditioning before SCT2 (p = 0.0272). Presented data indicate that second allograft is a feasible option in selected patients with relapsed acute leukemia. There is still room for improvement in terms of non-relapse mortality.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemiaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaAdultAllograftsDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedRecurrenceRetrospective StudiesRisk FactorsSurvival RateAcute leukemiaOutcomeRelapseSecond allogenic stem cell transplantationSurvival

Identifiers

PMID40608091
PMCPMC12432055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.